+

PL1740616T3 - Anti-tfr antibody. - Google Patents

Anti-tfr antibody.

Info

Publication number
PL1740616T3
PL1740616T3 PL04762981T PL04762981T PL1740616T3 PL 1740616 T3 PL1740616 T3 PL 1740616T3 PL 04762981 T PL04762981 T PL 04762981T PL 04762981 T PL04762981 T PL 04762981T PL 1740616 T3 PL1740616 T3 PL 1740616T3
Authority
PL
Poland
Prior art keywords
tfr antibody
antibody
tfr
relates
directed against
Prior art date
Application number
PL04762981T
Other languages
Polish (pl)
Inventor
Renato Monteiro
Olivier Hermine
Ivan Moura
Yves Lepelletier
Original Assignee
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Centre Nat Rech Scient filed Critical Inst Nat Sante Rech Med
Publication of PL1740616T3 publication Critical patent/PL1740616T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to the monoclonal antibody A24 directed against the transferrin receptor. This antibody is in particular useful as an antiproliferative agent.
PL04762981T 2004-04-30 2004-04-30 Anti-tfr antibody. PL1740616T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04762981A EP1740616B1 (en) 2004-04-30 2004-04-30 Anti-tfr antibody.
PCT/EP2004/005744 WO2005111082A1 (en) 2004-04-30 2004-04-30 Anti-tfr antibody.

Publications (1)

Publication Number Publication Date
PL1740616T3 true PL1740616T3 (en) 2012-06-29

Family

ID=34958155

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04762981T PL1740616T3 (en) 2004-04-30 2004-04-30 Anti-tfr antibody.

Country Status (8)

Country Link
US (1) US7976841B2 (en)
EP (1) EP1740616B1 (en)
AT (1) ATE537189T1 (en)
DK (1) DK1740616T3 (en)
ES (1) ES2379526T3 (en)
PL (1) PL1740616T3 (en)
PT (1) PT1740616E (en)
WO (1) WO2005111082A1 (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009241589B2 (en) 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AR075798A1 (en) 2009-03-05 2011-04-27 Abbott Lab PROTEINS OF UNION TO IL-17 (INTERLEUQUINA 17)
EP2453892B1 (en) * 2009-07-16 2013-05-29 Institut National de la Santé et de la Recherche Medicale Pharmaceutical compositions and their use for treating cancer
TWI615405B (en) 2010-05-14 2018-02-21 艾伯維有限公司 IL-1 binding protein
UY33492A (en) 2010-07-09 2012-01-31 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
WO2012018790A2 (en) 2010-08-03 2012-02-09 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
PE20140981A1 (en) 2010-11-30 2014-08-20 Genentech Inc ANTIBODY FOR THE LOW AFFINITY HEMATENEPHALLIC BARRIER RECEPTOR AND ITS USES
BR112013015944A2 (en) 2010-12-21 2018-06-19 Abbvie Inc Bispecific double-domain alpha and beta variable domain immunoglobulins and their uses.
JP2014514313A (en) * 2011-04-20 2014-06-19 ロシュ グリクアート アクチェンゲゼルシャフト Methods and constructs for pH-dependent passage of the blood brain barrier
US9598496B2 (en) 2011-05-09 2017-03-21 Perseus Proteomics Inc. Antibody capable of specifically recognizing transferrin receptor
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
WO2019071023A1 (en) 2017-10-04 2019-04-11 Yale University Compositions and methods for making selenocysteine containing polypeptides
TWI450727B (en) 2011-12-29 2014-09-01 Ind Tech Res Inst Single domain antibody against human transferrin receptor and its application
EP3505534A1 (en) 2012-06-08 2019-07-03 Sutro Biopharma, Inc. Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use
US9670276B2 (en) 2012-07-12 2017-06-06 Abbvie Inc. IL-1 binding proteins
US20150197574A1 (en) * 2012-08-02 2015-07-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of transferrin receptor antagonist for the treatment of thalassemia
EP3584255B1 (en) 2012-08-31 2022-02-16 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
RS57696B1 (en) 2012-11-08 2018-12-31 Univ Miyazaki Antibody capable of specifically recognizing transferrin receptor
EP2971047A4 (en) * 2013-03-15 2016-11-30 Alper Biotech Llc Monoclonal antibodies to transferrin and transferrin receptor antigens, and uses thereof
CA2907181C (en) 2013-03-15 2023-10-17 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
ES2970063T3 (en) 2013-05-20 2024-05-24 Hoffmann La Roche Anti-transferrin receptor antibodies and procedures for use
US9499628B2 (en) * 2013-06-14 2016-11-22 Children's Hospital Medical Center Method of boosting the immune response in neonates
EP3336103B1 (en) 2013-07-10 2021-03-17 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US9840493B2 (en) 2013-10-11 2017-12-12 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
FI3218005T3 (en) 2014-11-12 2023-03-31 Seagen Inc GLYCAN INTERACTING COMPOUNDS AND METHODS OF USE
CN107001473B (en) 2014-11-19 2021-07-09 豪夫迈·罗氏有限公司 Anti-transferrin receptor antibodies and methods of use
JP6993228B2 (en) 2014-11-19 2022-03-03 ジェネンテック， インコーポレイテッド Anti-transferrin receptor / anti-BACE1 multispecific antibody and usage
PL3292149T3 (en) 2015-05-04 2022-03-21 Cytomx Therapeutics, Inc. Activatable anti-cd71 antibodies, and methods of use thereof
PT3325509T (en) * 2015-07-22 2021-03-12 Inatherys Anti-tfr antibodies and their use in treating proliferative and inflammatory disorders
MX2018005061A (en) 2015-11-12 2019-02-28 Siamab Therapeutics Inc Glycan-interacting compounds and methods of use.
WO2017218698A1 (en) 2016-06-15 2017-12-21 Sutro Biopharma, Inc. Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
CA3054939A1 (en) 2017-03-03 2018-09-07 Seattle Genetics, Inc. Glycan-interacting compounds and methods of use
KR20190134654A (en) 2017-03-09 2019-12-04 싸이톰스 테라퓨틱스, 인크. CD147 antibody, activatable CD147 antibody, and how to make and use it
WO2019173771A1 (en) 2018-03-09 2019-09-12 Cytomx Therapeutics, Inc. Activatable cd147 antibodies and methods of making and use thereof
EP3552631A1 (en) 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer
US20210186880A1 (en) 2018-08-03 2021-06-24 Brown University Oral formulations with increased uptake
KR20210093974A (en) 2018-11-20 2021-07-28 가부시키가이샤 페르세우스 프로테오믹스 Intracellular iron uptake inhibitors
US20220242871A1 (en) 2019-06-10 2022-08-04 Sutro Biopharma, Inc. 5H-PYRROLO[3,2-d]PYRIMIDINE-2,4-DIAMINO COMPOUNDS AND ANTIBODY CONJUGATES THEREOF
JP2022536800A (en) 2019-06-17 2022-08-18 ストロ バイオファーマ インコーポレーテッド 1-(4-(aminomethyl)benzyl)-2-butyl-2H-pyrazolo[3,4-C]quinolin-4-amine derivatives and related compounds as TOLL-like receptor (TLR) 7/8 agonists, and antibody drug conjugates thereof for use in cancer therapy and diagnosis
WO2021045184A1 (en) 2019-09-04 2021-03-11 株式会社ペルセウスプロテオミクス Therapeutic agent for polycythemia
WO2021061867A1 (en) 2019-09-23 2021-04-01 Cytomx Therapeutics, Inc. Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof
CN114786718A (en) 2019-11-27 2022-07-22 株式会社英仙蛋白质科学 Drugs for cancer peritonitis
US20230095053A1 (en) 2020-03-03 2023-03-30 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
WO2021218862A1 (en) 2020-04-26 2021-11-04 Biocytogen Pharmaceuticals (Beijing) Co., Ltd Modified immunoglobulins
US20230060040A1 (en) * 2020-06-29 2023-02-23 Kunming Institute Of Zoology, Chinese Academy Of Sciences USE OF TRANSFERRIN, TRANSFERRIN RECEPTOR AND ANTIBODY THEREOF IN PREPARATION OF ANTI-SARS-CoV-2 DRUG
JPWO2022075439A1 (en) 2020-10-08 2022-04-14
WO2022103983A2 (en) 2020-11-11 2022-05-19 Sutro Biopharma, Inc. Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use
US20250163144A1 (en) 2021-07-27 2025-05-22 Novab, Inc. Engineered vlrb antibodies with immune effector functions
CN117836003A (en) 2021-08-26 2024-04-05 株式会社英仙蛋白质科学 ROS (reactive oxygen species) production enhancer
CR20240139A (en) 2021-09-01 2024-06-14 Biogen Ma Inc Anti-transferrin receptor antibodies and uses thereof
US20250144042A1 (en) 2022-02-22 2025-05-08 Brown University Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
CN119031936A (en) 2022-04-19 2024-11-26 学校法人东海大学 Therapeutic agents for NK cell tumors
IL316919A (en) 2022-06-27 2025-01-01 Sutro Biopharma Inc Beta-glucuronide carrier linkers, protein conjugates thereof and methods therefor
CN119948030A (en) 2022-07-15 2025-05-06 苏特罗生物制药公司 Protease/enzyme cleavable linker-payload and protein conjugates
EP4477236A1 (en) 2023-06-14 2024-12-18 Inatherys Combination therapy for treating a tumor using adc comprising anti-cd71 antibodies and bh3 mimetics
WO2025024334A1 (en) 2023-07-21 2025-01-30 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods
WO2025029832A2 (en) 2023-07-31 2025-02-06 Sutro Biopharma, Inc. Sting agonist compounds and conjugates
WO2025080711A1 (en) 2023-10-13 2025-04-17 Sutro Biopharma, Inc. Dual payload antibody drug conjugates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH05505823A (en) * 1990-03-27 1993-08-26 ザ・ソーク・インスティチュート・フォー・バイオロジカル・スタディーズ Cell growth inhibition method and compositions useful therein
CN1119726C (en) * 1997-12-19 2003-08-27 阿苏拉布股份有限公司 Display assembly comprising two superposed display devices
US6542146B1 (en) * 1999-05-27 2003-04-01 Lear Corporation Transparent electroluminescent display with mechanical gauge

Also Published As

Publication number Publication date
EP1740616B1 (en) 2011-12-14
EP1740616A1 (en) 2007-01-10
US7976841B2 (en) 2011-07-12
PT1740616E (en) 2012-03-23
WO2005111082A1 (en) 2005-11-24
ES2379526T3 (en) 2012-04-27
ATE537189T1 (en) 2011-12-15
US20080193453A1 (en) 2008-08-14
DK1740616T3 (en) 2012-03-26

Similar Documents

Publication Publication Date Title
PL1740616T3 (en) Anti-tfr antibody.
IL272883A (en) Monoclonal antibodies and uses thereof
HRP20181218T1 (en) Humanized anti-il-6 antibodies, compositions, methods and uses
IL184152A0 (en) Monoclonal antibodies against nkg2a
TWI369992B (en) Her2 antibody composition
ZA200710855B (en) Anti-IGF1R antibody formulations
IL187710A0 (en) Anti-trkb monoclonal antibodies and uses thereof
IL176755A0 (en) M-csf-specific monoclonal antibody and uses thereof
IL237756A0 (en) Antibody formulations
EP1765868A4 (en) Transferrin receptor antibodies
GB2430883B (en) Interleukin-13 antibody composition
IL180852A0 (en) Anti-cd154 antibodies
EP1728801A4 (en) Subtype of humanized antibody against interleukin-6 receptor
ZA200802051B (en) Anti-CD3 antibody formulations
EP1784425A4 (en) Anti-mcp-1 antibodies, compositions, methods and uses
ZA200706185B (en) Monoclonal antibodies against NKG2A
GB0415644D0 (en) Monoclonal antibody
HUE039022T2 (en) Interleukin-13 antibody composition
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载